

DRUGS CONTROL ADMINISTRATION Government of Telangana



CERTIFICATE OF A PHARMACEUTICAL PRODUCT^1

No of Certificate: 4276244/TS/2024

Valid UpTo: 27/06/2025

1. Name and Dosage form of Product:

Exporting(Certifying)Country:

Importing(Requesting) country

INDIA

Moldova

Deferasirox Tablets 180 mg Each Film Coated Tablet Contains Deferasirox 180

mg

1.1 Active Ingredients(s)^2 and amount(s) per unit dose^3:

Active ingredients (s): Deferasirox IH 180.00 mg

For complete composition including excipients, see attached:

Cellulose Microcrystalline (Avicel PH 102) Ph. Eur 54.290 mg

Croscarmellose sodium (Ac-Di-Sol) Ph.Eur 7.500 mg Low substituted Hydroxypropyl cellulose (L-HPC LH 21)

Ph.Eur 4.00 mg

> Poloxamer 188 (Kolliphor P 188) Ph.Eur 0.660 mg Povidone K 30 (Plasdone K29/32) Ph. Eur 8.250 mg

> > Purified water Ph.Eur Q.S

Lactose Monohydrate (Supertab 30 GR) Ph.Eur 54.050 mg

Croscarmellose Sodium (Ac-Di-Sol) Ph.Eur 7.500 mg

Low -substituited Hydroxypropyl cellulose (L-HPC LH 21) Ph.Eur 4.00 mg

Silica Colloidal

anhydrous (HDK N20) Ph.Eur 1.500 mg

Sodium stearyl fumarate (Alubra PG 100) Ph. Eur 2.350 mg Hydrogenated Castor oil (Kolliwax HCO) Ph.Eur 5.900 mg Opadry Yellow 03H520019 IH 10.00 mg

Purified water Ph.Eur Q.S

For complete qualitative composition including excipients see above 4

1.2 Is this Product licensed to be placed on the market for use in Exporting country?^5

Yes

1.3 Is this product actually on the marketing in the Exporting Country?

Yes

If the answer to 1.2 is Yes, continue with section 2A and omit section 2B. If the answer to 1.2 is No, omit section 2A continue with section 2B^6

Attested

2A.1 Number of Product Licence^7: Lic.No. 5/MN/TS/2014/F/G Dated: 26/08/2019 S.No: 189

2A.2 Product License Holder(Name and address): M/s MSN LABORATORIES PRIVATE LIMITED, Formulation Division, Unit-II, Sy. No.1277 & 1319 to 1324, Nandigama (Village & Mandal), Rangareddy District -509228, Telangana State, India.

2A.3 Status of License Holders^8: a

2B2.1 For Categories (b) and (c) the name and address of the manufacturer producing the dosage

2B.1 Applicant for Certificate(Name and Address)

form is^9

2A.3.1 For Category b and c the name and address of the manufacturer producing the dosage form is ^9 na

2A.4 Is Summary basis of approval appended? ^10 No

2B.3 Why is marketing authorisation lacking?

2B.4 Remarks^13:

2B.2 Status of Applicant^8

2A.5 Is the Attached, officially approved production information complete and consonant with the license?^11: Not Provided

Shalini Bansal 2A.6 Applicant lo Acertificate Los ferent from licence holder ssistant Director

(name and address) na

ATTESTED

http://www

DDY, B.Com., B.L., ADVOC/ E & NOTARY

Appointed by Govt., India G.O.Ms.No.198, Rev (Regn-II), dt. 11.04.2000 102. Saraswathi Enclave, Bhagyanagar Colony ukatpally, Hyderabad, TS India (Ph:98480 44395

2 2 MAR 2024

VEW DELHI, INDV

IMAR RE NOTAR Reon No 1 NOTARIAL



DRUGS CONTROL ADMINISTRATION Government of Telangana



3 Does the certifying authority arrange for periodic spection of the manufacturing plant in which the dosage form is produced?^14

Yes

3.1 Periodicity of routine inspection(years)

Once in a Year

3.2 Has the Manufacture of this type of dosage from been inspected?

Yes

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organization?^15

Yes

4.0 Does the information Submitted by the applicant satisfy the certifying authority on all aspects of the

manufacture of the product?^16

Yes

Address of Certifying Authority.

Name of the authorized person:

Drugs Control Administration, Vengalraonagar, Hyderabad500038, India

Digitally Signed By B SOWBHAGYA JAXMI

Telephone No: 91-040-23814119 Fax No: 91-040-23814360

Deputy Director and Ce lifying Authority

DRUGS CONTROL AMINISTRATION TELANGANA STATE

Date:11-03-2024 17:30:51 PM

This certificate conforms to the format recommended by the World Health Organization (General instructions and explanatory notes overleaf)





Men



(9)

